80 related articles for article (PubMed ID: 23092832)
41. Ototoxicity: bioprotective mechanisms.
Rybak LP; Kelly T
Curr Opin Otolaryngol Head Neck Surg; 2003 Oct; 11(5):328-33. PubMed ID: 14502062
[TBL] [Abstract][Full Text] [Related]
42. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Sasse AD; Clark LG; Sasse EC; Clark OA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):784-91. PubMed ID: 16198504
[TBL] [Abstract][Full Text] [Related]
43. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
44. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
45. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
46. Understanding platinum-induced ototoxicity.
Langer T; am Zehnhoff-Dinnesen A; Radtke S; Meitert J; Zolk O
Trends Pharmacol Sci; 2013 Aug; 34(8):458-69. PubMed ID: 23769626
[TBL] [Abstract][Full Text] [Related]
47. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
48. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
49. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
50. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Freyer DR; Brock P; Knight K; Reaman G; Cabral S; Robinson PD; Sung L
Lancet Child Adolesc Health; 2019 Aug; 3(8):578-584. PubMed ID: 31160205
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of cisplatin ototoxicity and progress in otoprotection.
Rybak LP
Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555
[TBL] [Abstract][Full Text] [Related]
52. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
53. Future opportunities in preventing cisplatin induced ototoxicity.
van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
[TBL] [Abstract][Full Text] [Related]
54. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
55. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
56. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
Hospers GA; Eisenhauer EA; de Vries EG
Br J Cancer; 1999 May; 80(5-6):629-38. PubMed ID: 10360638
[TBL] [Abstract][Full Text] [Related]
57. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.
Mell LK; Malik R; Komaki R; Movsas B; Swann RS; Langer C; Antonadou D; Koukourakis M; Mundt AJ
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):111-8. PubMed ID: 17289291
[TBL] [Abstract][Full Text] [Related]
58. Randomized trials of amifostine and radiotherapy: effect on survival?
Bourhis J; Thephamongkhol K; Pignon JP
Semin Oncol; 2004 Dec; 31(6 Suppl 18):62-6. PubMed ID: 15726526
[TBL] [Abstract][Full Text] [Related]
59. Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
Devine A; Marignol L
Anticancer Res; 2016 Jan; 36(1):5-12. PubMed ID: 26722022
[TBL] [Abstract][Full Text] [Related]
60. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
